Unknown

Dataset Information

0

Computationally driven deletion of broadly distributed T cell epitopes in a biotherapeutic candidate.


ABSTRACT: Biotherapeutics are subject to immune surveillance within the body, and anti-biotherapeutic immune responses can compromise drug efficacy and patient safety. Initial development of targeted antidrug immune memory is coordinated by T cell recognition of immunogenic subsequences, termed "T cell epitopes." Biotherapeutics may therefore be deimmunized by mutating key residues within cognate epitopes, but there exist complex trade-offs between immunogenicity, mutational load, and protein structure-function. Here, a protein deimmunization algorithm has been applied to P99 beta-lactamase, a component of antibody-directed enzyme prodrug therapies. The algorithm, integer programming for immunogenic proteins, seamlessly integrates computational prediction of T cell epitopes with both 1- and 2-body sequence potentials that assess protein tolerance to epitope-deleting mutations. Compared to previously deimmunized P99 variants, which bore only one or two mutations, the enzymes designed here contain 4-5 widely distributed substitutions. As a result, they exhibit broad reductions in major histocompatibility complex recognition. Despite their high mutational loads and markedly reduced immunoreactivity, all eight engineered variants possessed wild-type or better catalytic activity. Thus, the protein design algorithm is able to disrupt broadly distributed epitopes while maintaining protein function. As a result, this computational tool may prove useful in expanding the repertoire of next-generation biotherapeutics.

SUBMITTER: Salvat RS 

PROVIDER: S-EPMC4234684 | biostudies-literature | 2014 Dec

REPOSITORIES: biostudies-literature

altmetric image

Publications

Computationally driven deletion of broadly distributed T cell epitopes in a biotherapeutic candidate.

Salvat Regina S RS   Parker Andrew S AS   Guilliams Andrew A   Choi Yoonjoo Y   Bailey-Kellogg Chris C   Griswold Karl E KE  

Cellular and molecular life sciences : CMLS 20140601 24


Biotherapeutics are subject to immune surveillance within the body, and anti-biotherapeutic immune responses can compromise drug efficacy and patient safety. Initial development of targeted antidrug immune memory is coordinated by T cell recognition of immunogenic subsequences, termed "T cell epitopes." Biotherapeutics may therefore be deimmunized by mutating key residues within cognate epitopes, but there exist complex trade-offs between immunogenicity, mutational load, and protein structure-fu  ...[more]

Similar Datasets

| S-EPMC5739537 | biostudies-literature
| S-EPMC4896725 | biostudies-literature
| S-EPMC6690779 | biostudies-literature
| S-EPMC4456283 | biostudies-literature
| S-EPMC4233687 | biostudies-literature
| S-EPMC6612916 | biostudies-literature
| S-EPMC3090662 | biostudies-literature
| S-EPMC7944441 | biostudies-literature
| S-EPMC4288714 | biostudies-literature
| S-EPMC6349862 | biostudies-literature